{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:48:19Z","timestamp":1791406099739,"version":"4.3.3"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,8,1]]},"abstract":"<jats:p> Purpose: A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors. <\/jats:p><jats:p> Patients and Methods: The drug was delivered by a 10-minute weekly infusion for 3 weeks followed by a week gap, with intrapatient dose escalation. Dose escalation was accomplished by doubling until grade 2 toxicity was seen. The starting dose was 5 mg\/m<jats:sup>2<\/jats:sup>. <\/jats:p><jats:p> Results: Thirty-four patients received 167 infusions. CA4P was rapidly converted to the active combretastatin A4 (CA4), which was further metabolized to the glucuronide. CA4 area under the curve (AUC) increased from 0.169 at 5 mg\/m<jats:sup>2<\/jats:sup> to 3.29 \u03bcmol \u2022 h\/L at 114 mg\/m<jats:sup>2<\/jats:sup>. The mean CA4 AUC in eight patients at 68 mg\/m<jats:sup>2<\/jats:sup> was 2.33 \u03bcmol \u2022 h\/L compared with 5.8 \u03bcmol \u2022 h\/L at 25 mg\/kg (the lowest effective dose) in the mouse. The only toxicity that possibly was related to the drug dose up to 40 mg\/m<jats:sup>2<\/jats:sup> was tumor pain. Dose-limiting toxicity was reversible ataxia at 114 mg\/m<jats:sup>2<\/jats:sup>, vasovagal syncope and motor neuropathy at 88 mg\/m<jats:sup>2<\/jats:sup>, and fatal ischemia in previously irradiated bowel at 52 mg\/m<jats:sup>2<\/jats:sup>. Other drug-related grade 2 or higher toxicities seen in more than one patient were pain, lymphopenia, fatigue, anemia, diarrhea, hypertension, hypotension, vomiting, visual disturbance, and dyspnea. One patient at 68 mg\/m<jats:sup>2<\/jats:sup> had improvement in liver metastases of adrenocortical carcinoma. <\/jats:p><jats:p> Conclusion: CA4P was well tolerated in 14 of 16 patients at 52 or 68 mg\/m<jats:sup>2<\/jats:sup>; these are doses at which tumor blood flow reduction has been recorded. <\/jats:p>","DOI":"10.1200\/jco.2003.05.185","type":"journal-article","created":{"date-parts":[[2003,6,17]],"date-time":"2003-06-17T00:35:02Z","timestamp":1055810102000},"page":"2815-2822","source":"Crossref","is-referenced-by-count":276,"title":["Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results"],"prefix":"10.1200","volume":"21","author":[{"given":"Gordon J.S.","family":"Rustin","sequence":"first","affiliation":[{"name":"From the Department of Medical Oncology and Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex; Cancer Research United Kingdom Positron Emission Tomography Oncology Group, Hammersmith Hospital, London; and Cancer Research United Kingdom, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Galbraith","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology and Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex; Cancer Research United Kingdom Positron Emission Tomography Oncology Group, Hammersmith Hospital, London; and Cancer Research United Kingdom, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Anderson","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology and Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex; Cancer Research United Kingdom Positron Emission Tomography Oncology Group, Hammersmith Hospital, London; and Cancer Research United Kingdom, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stratford","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology and Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex; Cancer Research United Kingdom Positron Emission Tomography Oncology Group, Hammersmith Hospital, London; and Cancer Research United Kingdom, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Folkes","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology and Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex; Cancer Research United Kingdom Positron Emission Tomography Oncology Group, Hammersmith Hospital, London; and Cancer Research United Kingdom, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"Sena","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology and Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex; Cancer Research United Kingdom Positron Emission Tomography Oncology Group, Hammersmith Hospital, London; and Cancer Research United Kingdom, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Gumbrell","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology and Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex; Cancer Research United Kingdom Positron Emission Tomography Oncology Group, Hammersmith Hospital, London; and Cancer Research United Kingdom, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"Price","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology and Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex; Cancer Research United Kingdom Positron Emission Tomography Oncology Group, Hammersmith Hospital, London; and Cancer Research United Kingdom, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1139\/v82-202"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01954881"},{"key":"R3","unstructured":"Pettit GR, Temple C Jr, Narayanan VL, et al: Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10:299,1995\u2013309,"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(83)90163-6"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.320"},{"key":"R6","unstructured":"Dark GG, Hill SA, Prise VE, et al: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 57:1829,1997\u20131834,"},{"key":"R7","unstructured":"Chaplin DJ, Pettit GR, Hill SA: Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 19:189,1999\u2013195,"},{"key":"R8","unstructured":"Pedley R, Hill S, Boxer G, et al: Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 61:4716,2001\u20134722,"},{"key":"R9","unstructured":"Tozer GM, Prise VE, Wilson J, et al: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 59:1626,1999\u20131634,"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6692174"},{"key":"R11","unstructured":"Watts ME, Woodcock M, Arnold S, et al: Effects of novel and conventional anti-cancer agents on human endothelial permeability: Influence of tumour secreted factors. Anticancer Res 17:71,1997\u201375,"},{"key":"R12","unstructured":"Galbraith SM, Chaplin DJ, Lee F, et al: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21:93,2001\u2013102,"},{"key":"R13","unstructured":"Dowlati A, Robertson K, Cooney M, et al: A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408,2002\u20133416,"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.187"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.186"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.15.1138"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00458-7"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81848-6"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006314501634"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1010"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1080\/09553009114552251"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.1999.00534.x"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1982.16"},{"key":"R25","unstructured":"Grosios K, Loadman PM, Swaine DJ, et al: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20:229,2000\u2013233,"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00320-4"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.05.185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:31:10Z","timestamp":1653510670000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.05.185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,1]]},"references-count":25,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2003,8,1]]}},"alternative-id":["10.1200\/JCO.2003.05.185"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.05.185","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,1]]}}}